Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depression spectrum disorders and differential effects of newer antidepressants on driving safety
2009-016953-16Phase 4Active
- Sponsor
- Inn-Salzach-Klinikum
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of escitalopram, mirtazapine, bupropion and agomelatine in major depressive episode (MDE) and recurrent depressive disorder (RDD) (5 arms), sponsored by Inn-Salzach-Klinikum. Primary endpoint: Primary: discharge from inpatient treatment. Started Jan 2010; status: active.
02
Drugs
escitaloprammirtazapinebupropionagomelatine
03
Conditions
major depressive episode (MDE)recurrent depressive disorder (RDD)
Beyond the preview
Go deeper on 2009-016953-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016953-16.